Management of immune thrombocytic purpura and acute coronary syndrome: A double-edged sword!

被引：6

作者：

Shah, Ashish H. ^{[1
]}

Anderson, Richard A. ^{[2
]}

Khan, Ali Raza ^{[3
]}

Kinnaird, Timothy D. ^{[2
]}

机构：

[1] Univ Hlth Network, Toronto, ON, Canada

[2] Univ Wales Hosp, Cardiovasc Med, Cardiff, Wales

[3] Univ Wales Hosp, Dept Haematol, Cardiff, Wales

来源：

HELLENIC JOURNAL OF CARDIOLOGY | 2016年 / 57卷 / 04期

关键词：

Immune thrombocytopenic purpura; Coronary angioplasty; Stent thrombosis; Optical coherence tomography; INTRAVENOUS IMMUNOGLOBULIN; RISK; CLOPIDOGREL; THROMBOSIS; THERAPY;

D O I：

10.1016/j.hjc.2014.10.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Treating patients known to have immune thrombocytopenic purpura (ITP) presenting with acute coronary syndrome (ACS) pose challenges, especially if they undergo percutaneous coronary intervention and stenting, as they require certain period of dual antiplatelet medication based up on the type of stent been deployed. Co-existence of therapies to increase platelet number as well as anti-platelet efficacy at the same time appears contradictory; imbalance in antagonistic treatment approach of increasing platelet number to treat ITP and inhibiting their activity to treat ACS can result in life threatening complications. (C) 2016 Hellenic Cardiological Society. Publishing services by Elsevier B. V. This is an open access article under the CC BY-NC-ND license.

引用

页码：273 / 276

页数：4

共 14 条

[1] Medical progress: Immune thrombocytopenic purpura. [J].